drugset / Trial / NCT06533657
Unique Treatment of Oncology Pain in Advanced Cancer
NaSingle-groupOpen-labelTreatment
Summary
This will be a proof-of-concept, single arm study with a maximum of 20 patients to evaluate preliminary analgesic efficacy and safety of Trichomylin® in patients with advanced cancer (male and female) who suffer from moderate to severe chronic pain and who are taking a stable dose of long-acting opioid therapy for at least 1 week prior to screening.
Timeline
- Start
- 2025-06-12
- Primary completion
- 2026-04-15
- Completion
- 2026-04-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trichomylin | Unknown | 5 mg | Oral |
Indications
No indication recorded.